Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Blinded, Positive and Placebo-controlled Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SARS-CoV-2 Bivalent mRNA Vaccine (LVRNA021) Booster Vaccination in People 18 Years of Age and Older Who Have Received SARS-CoV-2 Vaccine.

NCT05939648 is registered in ClinicalTrials.gov with AIM Vaccine Co., Ltd. as lead sponsor.

NCT NCT05939648
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05939648 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Blinded, Positive and Placebo-controlled Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SARS-CoV-2 Bivalent mRNA Vaccine (LVRNA021) Booster Vaccination in People 18 Years of Age and Older Who Have Received SARS-CoV-2 Vaccine.
Lead sponsor
AIM Vaccine Co., Ltd.
Phase
Phase 2
Overall status
Unknown status
Start date
October 9, 2023
Completion date
December 30, 2024
Enrollment
450 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

sars-cov-2